A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Latest Information Update: 06 Jul 2020
At a glance
- Drugs Gosuranemab (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Acronyms CN002-003
- Sponsors Biogen; Bristol-Myers Squibb
Most Recent Events
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 12 Jul 2017 Status changed from active, no longer recruiting to completed.
- 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.